Posted by Michael Wonder on 23 May 2020
U.S. FDA approves Takeda’s Alunbrig (brigatinib) as a first-line treatment option for patients diagnosed with rare and serious form of lung cance
22 May 2020 - Long-term results from the Phase 3 ALTA 1L trial established Alunbrig as a superior first-line treatment compared to crizotinib for people with ALK+ metastatic non-small cell lung cancer, including those with brain metastases.
Takeda today announced that the U.S. FDA approved Alunbrig (brigatinib) for adult patients with anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer as detected by an FDA-approved test.
This approval expands Alunbrig’s current indication to include the first-line setting.
